Paolo Compagnucci, Adelina Selimi, Laura Cipolletta, Giovanni Volpato, Alessio Gasperetti, Yari Valeri, Quintino Parisi, Antonio Curcio, Andrea Natale, Antonio Dello Russo, Michela Casella
Although mitral valve prolapse (MVP) is the most prevalent valvular abnormality in Western countries and generally carries a good prognosis, a small subset of patients is exposed to a significant risk of malignant ventricular arrhythmias (VAs) and sudden cardiac death (SCD), the so-called arrhythmic MVP (AMVP) syndrome. Recent work has emphasized phenotypical risk features of severe AMVP and clarified its pathophysiology. However, the appropriate assessment and risk stratification of patients with suspected AMVP remains a clinical conundrum, with the possibility of both overestimating and underestimating the risk of malignant VAs, with the inappropriate use of advanced imaging and invasive electrophysiology study on one hand, and the catastrophic occurrence of SCD on the other...
February 27, 2024: Journal of Clinical Medicine